Who are Pegylated interferon alpha 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intron A, PegIFN alfa-2a, Peg-IFN α-2b combined with NAs, Placebo and peginterferon, Peg-IFNα-2a, Peginterferon alfa 2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegylated-interferon-alpha-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pegylated interferon alpha 2 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegylated interferon alpha 2 (Pegylated interferon alpha 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha. Area: Immunology, Virology, Oncology.

marketed Interferon alpha Interferon-alpha receptor (IFNAR) Immunology, Virology, Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pegylated interferon alpha 2 (Pegylated interferon alpha 2) — Ain Shams University. Pegylated interferon alpha-2 activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pegylated interferon alpha 2 TARGET	Pegylated interferon alpha 2	Ain Shams University	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Intron A	INTERFERON ALFA-2B	Merck & Co.	marketed	Interferon alpha		1986-01-01
PegIFN alfa-2a	PegIFN alfa-2a	The Second Affiliated Hospital of Chongqing Medical University	marketed	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
Peg-IFN α-2b combined with NAs	Peg-IFN α-2b combined with NAs	Shenzhen Third People's Hospital	marketed	Interferon alpha combined with nucleos(t)ide reverse transcriptase inhibitor	Interferon-alpha receptor (IFNAR); HBV reverse transcriptase
Placebo and peginterferon	Placebo and peginterferon	National Taiwan University Hospital	marketed	Interferon alpha (pegylated)	Interferon-alpha receptor (IFNAR)
Peg-IFNα-2a	Peg-IFNα-2a	Beijing 302 Hospital	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa 2	Peginterferon alfa 2	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha class)

Dr. Conrado Fernandez · 2 drugs in this class
Ain Shams University · 1 drug in this class
Beijing 302 Hospital · 1 drug in this class
Foundation for Liver Research · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Kexing Biopharm Co., Ltd. · 1 drug in this class
Merck & Co. · 1 drug in this class
ANRS, Emerging Infectious Diseases · 1 drug in this class
Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegylated interferon alpha 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-interferon-alpha-2. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing